Moderna filed regulatory applications in the U.S., EU, Canada and Australia for its mRNA seasonal influenza vaccine mRNA‑1010, targeting adults aged 50 and older. The company pitched faster design cycles enabled by mRNA technology as an advantage for strain matching; Phase 3 data showed a 27% risk reduction in influenza illness versus marketed comparator shots in people 50+. CEO Stéphane Bancel framed respiratory vaccines as a near‑term revenue growth driver to offset COVID‑era declines and support Moderna’s pipeline investment in oncology and rare disease. The filing follows Moderna’s strategic retrenchment after setbacks including a failed CMV Phase III and weak COVID vaccine sales. Regulators will scrutinize effectiveness and strain‑matching claims; a successful approval would validate mRNA as a broader vaccine modality beyond SARS‑CoV‑2 and RSV.